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A population-based case-control study on the
association between rheumatoid arthritis and deep
vein thrombosis
Jiunn-Horng Kang, MD, PhD,a,b Joseph J. Keller, MD, MPH,c Yen-Kuang Lin, PhD,d and
Herng-Ching Lin, PhD,e Taipei, Taiwan
Objective: Chronic inflammation has been associated with endothelial dysfunction and altered coagulation status.
However, at the present time, the data regarding the risk for developing deep vein thrombosis (DVT) in patients with
rheumatoid arthritis (RA) is still scanty and conflicted. This study aimed to explore the frequency and association of DVT
with RA using a population-based dataset.
Methods: This was a case-control study conducted in Taiwan. A total of 5193 patients with DVT were identified from the
Longitudinal Health Insurance Database 2000 (LHID2000) database. In total, 20,772 controls matched with cases in
terms of gender, age, and year of index date were randomly selected. We used conditional logistic regression to calculate
the odds ratio (OR) for having been previously diagnosed with RA between cases and controls.
Results:Of the total 25,965 sampled subjects, 235 (0.9%) had been previously diagnosed with RA. Seventy-seven of these
previous diagnoses were found among cases (1.5%) and 158 among controls (0.8%). Conditional logistic regression
analysis revealed that cases were more likely to have had prior RA than controls (OR, 1.92; 95% confidence interval [CI],
1.46-2.53; P < .001). After adjusting for hospitalization history, pregnancy, fracture, surgery, cancer, inflammatory
bowel disease, heart failure, hypertension, diabetes, coronary heart disease, hyperlipidemia, and renal disease, there was
still a significant association between DVT and prior RA (OR, 1.88; 95% CI, 1.42-2.58; P < .001).
Conclusions:We foundRA to be significantly associated withDVT. Appropriatemanagement should be taken tominimize
the risk of DVT in patients with RA. Further study is needed to confirm our findings. ( J Vasc Surg 2012;56:1642-8.)
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cDeep vein thrombosis (DVT) is a relatively common
medical emergency that can potentially result in morbidity
and long-term consequences.1 DVT and pulmonary em-
boli are prevalent causes of hospitalization-associated mor-
tality.1,2 Several conditions are recognized to be associated
with a higher risk of developing DVT, including heart
failure, malignancy, and fracture. Major surgery and brief
periods of immobilization are considered to be major risk
factors associated with DVT. Adequate prophylaxis with
anticoagulants and other management (such as compres-
sion stockings and adherence to early mobilization pro-
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1642rams) are important in the prevention of DVT in high-risk
opulations.2
Rheumatoid arthritis (RA) is a chronic inflammatory
isorder mainly involving synovial joints. RA can involve
ultiple organs and have several systemic manifestations.3
hronic inflammation has been demonstrated to be associ-
ted with both endothelial dysfunction and altered coagula-
ion.4-7 PatientswithRAhave been suggested to possibly have
n increased risk of developing venous thromboembolism
VTE) events based on the high prevalence of many known
TE risk factors.8,9 However, although the largest study
onducted investigating this association to date suggested
n increased risk for DVT among patients with RA, there is
till controversy in the literature.10-15 Thus, at the present
ime, the data regarding the risk for developing DVT
mong patients with RA remain incomplete. In addition,
he current data regarding the association between DVT
nd RA have largely been obtained from hospitalization
nd postsurgical records, leaving the association between
VT and RA particularly sparse in both long-term and
utpatient contexts.
The data concerning the frequency and risk of DVT in
atients with RA are crucial to clinical management, as
roper decision-making should be based on the epidemio-
ogic profile. To obtain a representative sample with a
ufficient sample size, the present investigation aimed to
xplore the frequency of prior RA in patients with DVT
sing a large-scale population-based study. A retrospective
ase-control design was undertaken to estimate the poten-
ial association of RA with DVT.
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Database. The data for this population-based case-
control study were sourced from the Longitudinal Health
Insurance Database 2000 (LHID2000). The LHID2000
consists of all the original claims data and registration files
of 1,000,000 individuals randomly sampled from the 2000
Registry for Beneficiaries of the Taiwan National Health
Insurance (NHI) program and was created by the Taiwan
National Health Research Institute. These data are released
annually and cover over 99% of Taiwan’s population of 23
million. The LHID2000 was restricted to 1,000,000 pa-
tients, as in Taiwan, there are approximately 30 million
outpatient visits per month. Therefore, it would be impos-
sible to use a personal computer to sample from the entire
cohort. The TaiwanNational Health Research Institute has
validated the representativeness of the gender distribution
between the patients selected for inclusion in the
LHID2000 and all the patients enrolled under the NHI
program. Furthermore, prior studies have demonstrated
the high validity of the data from the NHI program.16,17
The LHID2000 provides an opportunity for researchers to
trace all the medical services of these selected 1,000,000
individuals since the beginning of the Taiwan NHI pro-
gram in 1995.
This study was exempted from full review by an insti-
tutional review board after consulting with the director of
the Taipei Medical University institutional review board
because the LHID2000 consists of deidentified secondary
data released to the public for research purposes.
Selections of cases and controls. We first used the
LHID2000 to identify 5193 patients aged 18 years with
a first-time diagnosis of DVT (International Classification
of Disease, 9th Revision, Clinical Modification [ICD-9-
CM] codes 453, 453.2, 453.3, 453.8, or 453.9) in their
visits to ambulatory care centers (including outpatient de-
partments of hospitals or clinics) or hospitalizations be-
tween January 2001 and December 2009. However, the
Taiwan NHI program was launched in March 1995, so the
LHID2000 only allowed us to trace medical service utili-
zations since 1996. Therefore, we could not rule out the
possibility that some cases might have already received a
diagnosis of DVT before 1996. In order to increase the
diagnostic validity of DVT in this study, we only included
patients with DVT who had received at least two DVT
diagnoses during the period between 2001 and 2009 inter-
spersed by a maximum of 1 month. In Taiwan, the first
diagnosis of a condition reflects the clinician’s utilization of
a diagnostic test to assess the condition in question,
whereas the second diagnosis indicates the presence of the
condition based on the outcome of both the diagnostic test
and a clinical examination. Therefore, by limiting our cases
to those that received two diagnoses, we ensured that all of
our cases received a positive diagnosis based on their symp-
toms, medical history, and the results of at least one diag-
nostic test. In Taiwan, the most common tests used in the
diagnosis of DVT are duplex ultrasound scan and venogra-
phy, but magnetic resonance imaging is often utilized in ahe differential diagnosis. The Fig shows the selection
riteria and process. We assigned the date of the first
iagnosis of DVT as the index date for cases.
We likewise used the LHID2000 to select four controls
or each case. In total, we retrieved 20,772 controls
atched with the cases in terms of gender, age in intervals
f 10 years (18-30, 30-39, 40-49, 50-59, 60-69, and
69), and year of index date. Whereas for cases, the year of
ndex date was the year in which the cases received their first
iagnosis of DVT, for controls, the year of index date was
imply a matched year in which controls had a medical
tilization. We assigned the date of their first use of medical
ervices occurring during that matched year as the index
ate for controls. We also ensured that no selected controls
ad ever received a diagnosis of DVT since the initiation of
he Taiwan NHI program.
Exposure assessment. We identified RA cases based
n the ICD-9-CM code 714.0. In Taiwan, RA is usually
iagnosed by rheumatologists. In order to increase the
alidity of RA diagnoses used in this study, we only selected
atients who had received two or more RA diagnoses
efore the index date, with at least one being made by a
heumatologist. Furthermore, we only included those RA
ases that had been prescribed at least one type of disease-
odifying antirheumatic drug (DMARD) before the index
ate.
Statistical analysis. We used the SAS system (SAS
ystem for Windows, Version 8.2, SAS Institute, Cary,
C) to perform all the statistical analyses performed in
his study. We first used 2 tests to compare the differences in
onthly income (NT$0-NT15,840, NT15,841-NT25,000,
 
7,423 patients 
Excluded 59 patients aged <18 years 
Excluded 2,171 patients only 
received a diagnosis of DVT 
Diagnosis of DVT (ICD-9-CM codes 
453, 453.2, 453.3, 453.8 or 453.9) 
7,364 patients 
5,193 patients 
LHID2000 
ig. Procedures of the case selections. DVT,Deep vein thrombo-
is; ICD-9-CM, International Classification of Disease, 9th Revi-
ion, Clinical Modification; LHID2000, Longitudinal Health In-
urance Database 2000.nd NT25,001), geographic location (Northern, Central,
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December 20121644 Kang et alEastern, and Southern Taiwan), and urbanization level of
the patient’s residence (5 levels, with 1 being the most
urbanized and 5 being the least) between cases and con-
trols. We also used conditional logistic regression (condi-
tioned on gender, age in 10-year intervals, and index year)
to calculate the odds ratio (OR) and its corresponding 95%
confidence interval (CI) for having been previously diag-
nosed with RA between cases and controls.
In the regression model, we also adjusted for potential
confounding factors, including whether or not a subject
was hospitalized, pregnant, had suffered a fracture or sur-
gery within 1 year before the index date, or was diagnosed
with cancer, inflammatory bowel disease, heart failure, hy-
pertension, diabetes, coronary heart disease (CHD), hyper-
lipidemia, or renal disease. Comorbidities were defined on
the basis of data obtained before the index date. Further-
more, we used the number of pharmaceuticals, (no
DMARDs, one type of DMARDs, two types of DMARDs,
and three types of DMARDs or tumor necrosis factor-
Table I. Demographic characteristics and medical comorb
Variable
Patients with DVT
(n  5193)
Total No.
Age (years)
18-39 554
40-49 729
50-59 977
60-69 1097
69 1836
Gender
Male 2143
Female 3050
Monthly income
NT$1 to 15,840 1997
NT$15,841 to 25,000 2446
NT$25,001 750
Geographic region
Northern 2810
Central 1150
Eastern 1106
Southern 127
Urbanization level
1 (most urbanized) 1394
2 1489
3 959
4 699
5 (least urbanized) 652
Hospitalization within 1 year 2831
Pregnancy within 1 year 123
Heart failure 1621
Inflammatory bowel disease 42
Cancer 1599
Surgery or fracture 1547
Hyperlipidemia 1357
Diabetes 1511
Hypertension 2591
CHD 1408
Renal disease 1222
CHD, Coronary heart disease; DVT, deep vein thrombosis; OR, odds ratio[TNF]- inhibitor) prescribed within the year before their (VT diagnosis. Use of TNF- inhibitor is associated with
reater clinical severity.18 We further analyzed the OR for
A according to their pharmaceutical prescriptions. The
onventional P  .05 was used to assess statistical signifi-
ance.
ESULTS
Table I presents the descriptive data for the sampled
ubjects. After matching for gender, age in 10-year in-
ervals, and index year, there was no significant differ-
nce in the distribution of monthly income or urbaniza-
ion level between cases and controls. However, several
omorbidities were more common among cases than
ontrols, including heart failure (31.2% vs 11.6%; P 
001), cancer (30.8% vs 17.6%; P  .001), inflammatory
owel disease (0.8% vs 0.5%; P  .005), hyperlipidemia
26.1% vs 23.5%; P  .001), diabetes (29.1% vs 21.0%;
 .001), hypertension (49.9% vs 43.1%; P  .001),
HD (27.1% vs 18.1%; P  .001), and renal disease
s of patients with DVT and controls (n  25,965)
Controls
(n  20,772)
% P valueTotal No.
1.000
2223 10.7
2908 14.0
3905 18.8
4383 21.1
7353 35.4
1.000
8578 41.3
12,193 58.7
.924
8039 38.7
9721 46.8
3013 14.5
.001
9597 46.2
5068 24.4
5567 26.8
540 2.6
.414
5463 26.3
5899 28.4
3843 18.5
3012 14.5
2555 12.3
3789 18.7 .001
548 2.7 .187
2351 11.6 .001
98 0.5 .005
3572 17.6 .001
4597 22.6 .001
4774 23.5 .001
4269 21.0 .001
8756 43.1 .001
3675 18.1 .001
1318 6.5 .001iditie
%
10.7
14.0
18.8
21.1
35.4
41.3
58.7
38.5
47.1
14.4
54.1
22.2
21.3
2.5
26.8
28.7
18.5
13.4
12.6
54.5
2.4
31.2
0.8
30.8
29.8
26.1
29.1
49.9
27.1
23.523.5% vs 6.5%; P  .001). Furthermore, patients were
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Volume 56, Number 6 Kang et al 1645more likely than controls to have been hospitalized
(54.5% vs 18.7%; P  .001) and have undergone a
surgical procedure or had a fracture (29.8% vs 22.6%;
P  .001) within 1 year before the index date.
Table II shows the prevalence of prior RA between
cases and controls. We found that of the 25,965 sampled
subjects, 235 (0.9%) had been diagnosed with RA before
the index date; 87 were found among the cases (1.6%) and
158 among the controls (0.8%). Conditional logistic re-
gression analysis (conditioned on gender, age in 10-year
Table II. Prevalence and crude ORs for RA among the sa
Presence of RA
Total
(n  25,965) n, %
Yes 245 0.9
Crude OR (95% CI) —
CI, Confidence interval; DVT, deep vein thrombosis; OR, odds ratio; RA,
OR was calculated by conditional logistic regression, which was conditione
aIndicates P  .001.
Table III. Covariate-adjusted odds ratios for DVT
among the sampled patients (n  25,965)
Variables
DVT
OR 95% CI P value
RA
Yes 1.93 1.41-2.62 .001
No (reference group) 1.00
Monthly income
NT$1 to 15,840 (reference
group) 1.00
NT$15,841 to 25,000 1.11 1.03-1.20 .006
NT$25,001 1.03 0.93-1.15 .531
Geographic region
Northern (reference group) 1.00
Central 0.66 0.61-0.73 .001
Eastern 0.60 0.55-0.65 .001
Southern 0.59 0.48-0.74 .001
Urbanization level
1 (reference group) 1.00
2 1.19 1.08-1.30 .001
3 1.36 1.22-1.51 .001
4 1.06 0.94-1.19 .364
5 1.27 1.11-1.44 .001
Hospitalization within 1 year 3.90 3.63-4.19 .001
Pregnancy within 1 year 1.21 0.98-1.48 .082
Heart failure 1.98 1.82-2.16 .001
Inflammatory bowel disease 0.91 0.78-1.05 .196
Cancer 1.46 1.35-1.57 .001
Surgery or fracture within 1 year 1.11 1.03-1.20 .007
Hyperlipidemia 1.09 1.01-1.18 .044
Diabetes 0.95 0.88-1.04 .263
Hypertension 0.87 0.81-0.94 .001
CHD 0.99 0.91-1.08 .079
Renal disease 2.79 2.53-3.08 .001
CHD, Coronary heart disease; CI, confidence interval; DVT, deep vein
thrombosis; OR, odds ratio; RA, rheumatoid arthritis.intervals, and index year) further revealed that cases were oore likely than controls to have been previously diag-
osed with RA (OR, 1.92; 95% CI, 1.46-2.53; P  .001).
Table III shows the covariate-adjusted OR for DVT
mong the sampled subjects. Conditional logistic regres-
ion analysis revealed that there was a significant association
etween DVT and prior RA (OR, 1.88) after adjusting for
onthly income, geographic location, urbanization level,
ospitalization, pregnancy, fracture or surgery, cancer, in-
ammatory bowel disease, heart failure, hypertension, dia-
etes, CHD, hyperlipidemia, and renal disease. The pseudo
-square was 0.289 for this logistic regression model. In
ddition, the area under the curve of the current model was
.753, which was significantly larger than the reference
evel of 0.5 (P  .001). It also showed that DVT was
ssociated with hospitalization (OR, 3.9), fracture or sur-
ery (OR, 1.1), cancer (OR, 1.46), heart failure (OR,
.98), and renal disease (OR, 2.79).
Table IV presents the prevalence and covariate-
djusted OR for RA according to their pharmaceutical
rescriptions. It shows that a very high proportion of
atients with RA who had been prescribed three types of
MARDs or TNF- inhibitors were found among cases as
ompared with controls (OR, 4.01; 95% CI, 2.12-7.58).
urthermore, there was a higher proportion of patients
ith RA who had been prescribed two types of DMARDs
mong cases than controls (OR, 4.00; 95% CI, 2.16-7.46).
ISCUSSION
We found that there was a significant association be-
ween RA and DVT. About 0.8% of the patients in the
ontrol group were diagnosed with RA. This figure is
enerally consistent with previous observations of RA prev-
lence in the general population.3 However, among the
193 patients who had DVT, 1.5% of the patients had a
istory of RA. TheOR of having previously been diagnosed
ith RA among DVT cases was 1.92 times that of the
ontrols.
Many patients with RA also had several comorbidities
r coexisting conditions associated with the development
f DVT, such as orthopedic surgery, fracture, heart disease,
enal disease, or a history of hospitalization. We took these
actors into consideration in an attempt to explore the
ndependent association between RA and DVT. After ad-
usting for these factors, the adjusted OR for prior RA in
atients who had DVT was still significant (OR, 1.88; P 
001). The results from our study are consistent with those
d patients
Patients with DVT
(n  5193) n, %
Controls
(n  20,772) n, %
87 1.6 158 0.8
1.96a (1.45-2.64) 1.00
atoid arthritis.
ender and age group.mple
rheumf a recent investigation performed at Oxford University.
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December 20121646 Kang et alRamagopalan et al14 showed that the risk of DVT and
pulmonary emboli was significantly higher among patients
who were admitted to hospitals with immune-mediated
diseases. They found the ORs for having DVT and pulmo-
nary emboli among patients with RA to be about 1.45 to
1.75 times that of a control cohort. Similarly, Russell et al19
used a large-scale managed care claims dataset to find an
association between RA and VTE. Although the findings of
these studies support the association between RA and
DVT, there is still conflict in the literature regarding this
association with the results of several studies refuting this
association.
One prior study refuting this association was a prospec-
tive study conducted by Niki et al11 in Japan investigating
the risk for DVT and pulmonary emboli in patients with RA
receiving total knee replacement. They found the risk of
DVT in patients with RA to be significantly lower than in
patients with osteoarthritis. However, the results and con-
clusions of this study may have been compromised for two
main reasons. First, they did not adjust for associated risk
factors. Second, they only had a short follow-up period (7
days). Similarly, two early retrospective studies also re-
ported lower symptomatic venous thromboembolism rates
in patients with RA after joint replacements.12,13 The con-
tradictory results of previous studies may have arisen due to
selection biases generated from collecting cases from a
single hospital, or on account of inadequate statistical
power due to small sample sizes.
The occurrence of venous thrombosis is linked to three
determinative factors, which comprise what is known as the
Virchow triad and include endothelial dysfunction due to
vessel wall injury, reduced velocity of regional blood flow,
and hypercoagulation status.
Although data were mainly obtained from an ar-
throsclerosis model, endothelial dysfunction has been dem-
onstrated extensively in RA.6,20,21 Several molecular mech-
anisms have recently been recognized in which chronic
Table IV. Prevalence and covariate-adjusted ORs for RA
Presence of RA (without receiving any DMARDs or TNF- inhib
Adjusted OR (95% CI)
Presence of RA (1 type of DMARDs)
Adjusted OR (95% CI)
Presence of RA (2 types of DMARDs)
Adjusted OR (95% CI)
Presence of RA (3 types of DMARDs or TNF- inhibitor)
Adjusted OR (95% CI)
CHD, Coronary heart disease; CI, confidence interval; DMARDs, disease-m
rheumatoid arthritis; TNF-, tumor necrosis factor-.
Adjusted OR was calculated by conditional logistic regression, which was con
location, urbanization level of the patient’s residence, and whether or not a
the index date, or received a diagnosis of cancer, inflammatory bowel diseas
aIndicates P  .05; bindicates P  .001.inflammation alters the balance of coagulation status, pro- aoting procoagulation.22 TNF- plays a vital role in the
athogenesis of RA.23 TNF- can alter the expression of
hrombomodulin in endothelial cells, which may impair
nticoagulant pathways.24 The initiation of the coagulation
ascade arising from endothelial dysfunction can, therefore,
romote venous thrombosis. Moreover, it has been re-
orted that an increased level of plasminogen activator
nhibitor in patients with RA can impair the process of
brinolysis.25,26 Hyperhomocysteinemia, which is known
o be a procoagulation condition, is also known to be fairly
ommon in patients with RA.27 Bidirectional interactions
f hyperhomocystemia can promote both autoimmunity-
ediated inflammation and coagulation.28
In addition to the above-mentioned endothelial and
oagulation factors, regional blood flow can be compro-
ised in patients with RAwith focal lesions. The swelling of
he inflamed iliopsoas bursa can cause compression of the
emoral vein, which is further associated with development
f DVT.29 Immobilization due to joint pain can also put
atients with RA at an increased risk for blood flow stasis
nd DVT. It is worth noting that not all adverse pathophys-
ological changes in patients with RA are prone to causing
he development of DVT. Patients with RA tend to have
ow hematocrit levels,30 which may lower the relative vis-
osity of the blood and the risk for DVT. However, the
rotective effects of these factors may not be dominant in
he overall pathogenesis of DVT.
RA is not a very common disease, and any epidemio-
ogic analysis needs to be based on a sufficient number of
epresentative cases. Previous studies have demonstrated
he feasibility of our study design by using administrative
atabases to provide relevant epidemiologic data regarding
he association between RA andDVT.14,19 However, some
imitations of our study should be addressed. First, the
oding accuracy in medical registry-based databases has a
arge impact on the results of studies conducting analyses
n that data. The validity of using the LHID2000 to
ding to pharmaceutical prescriptions
Patients with DVT
(n  5193)
Controls
(n  20,772)
No. % No. No.
16 0.3 38 0.2
1.79 (1.01-3.18) 1.00
32 0.6 83 0.4
1.54 (1.03-2.33) 1.00
19 0.4 17 0.1
4.00a (2.16-7.46) 1.00
20 0.4 20 0.1
4.01b (2.12-7.58) 1.00
ing antirheumatic drug; DVT, deep vein thrombosis; OR, odds ratio; RA,
ed on gender and age group and adjusted for monthly income, geographic
t was hospitalized, pregnant, had a fracture or surgery within 1 year before
rt failure, hypertension, diabetes, CHD, hyperlipidemia, or renal disease.accor
itors)
odify
dition
subjecnalyze epidemiologic issues can be seen from previous
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Volume 56, Number 6 Kang et al 1647studies.16,31,32 Second, laboratory and image result data
cannot be accessed from our database.
Third, although we adjusted for somemajor confound-
ing factors associated with DVT, other factors such as the
level of physical activity, cigarette smoking, body mass
index, contraceptive use, and family history cannot be
obtained from the database. These factors may also contrib-
ute to the development of DVT.Unfortunately, we also did
not have any data regarding screening rates for DVT
among the patient population analyzed in this investiga-
tion. Although it is possible that this may have caused our
study to suffer from an ascertainment bias, in which the
association detected in this study could be partly explained
by patients with RA being more likely to be diagnosed with
DVT purely on account of being sicker and their subse-
quently increased exposure to the medical community, we
feel that this effect was unlikely to have had a large impact
on our results. The Taiwan National Health Insurance
program has a number of characteristics, including ex-
tremely low out-of-pocket costs, a lack of gatekeepers to
specialist care, and access to a wide variety of convenient
options for medical care that may flatten the barriers to
medical care seen in many other regions of the world.
Therefore, we feel that any Taiwanese experiencing the
peculiar unilateral swelling characteristic of DVTwould not
hesitate to seek medical care.
Fourth, as this was a case-control study, we were unable
to assess causality and could only weakly comment on the
temporality of the association. We were further unable to
determine the effects of treatment on the association be-
tween RA and DVT. This is because the observational
nature of the case-control study design predisposes to
channeling bias, whereby patients with more severe disease
are more likely to be included in subgroups taking more
intensive courses of treatment such as anti-TNF therapy.18
So, although we may expect a stronger course of treatment
to reduce the association between RA and DVT, the po-
tentially more intense prothrombotic state and increased
immobility in the individuals with higher disease activity
taking more intensive therapy may very well overcome the
therapeutic effects of the medication. Therefore, future
investigations utilizing other study designs will be needed
to clarify temporality and causality, report estimates of risk,
and ascertain the effects of medication on this association.
Finally, the ethnic composition of subjects included in
the LHID2000 is mainly Han Chinese. As ethnic differ-
ences have been identified to have an effect on the occur-
rence of thromboembolic events,33 the confirmation of our
results is needed among other ethnic populations.
CONCLUSIONS
We found RA to be significantly associated with DVT.
Because the impact of DVT could be severe, the burden of
RA-associated DVT should not be overlooked. Although
the beneficial effects of prophylactic anticoagulant treat-
ment have been documented among patients receiving
major orthopedic surgery,2 further investigation will be
needed to both confirm our findings and establish adequateecommendations for the prophylactic management of
VT among patients with RA.
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